Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Jamaica, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Jamaica, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
New York, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Staten Island, NY
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Charlotte, NC
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Beachwood, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Beachwood, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Cincinnati, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Cincinnati, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes' Investigational Study Site
mi
from
Mason, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes' Investigational Study Site
mi
from
Mason, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Middleburg Heights, OH
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Portland, OR
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Salem, OR
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Salem, OR
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Study Site
mi
from
Philadelphia, PA
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Study Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Study Site
mi
from
Charleston, SC
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Study Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Memphis, TN
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Dallas, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Dallas, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Houston, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Sugarland, TX
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Sugarland, TX
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Bellevue, WA
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Waukesha, WI
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Waukesha, WI
Click here to add this to my saved trials
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated:  2/3/2016
Alkermes Investigational Site
mi
from
Bourgas,
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)
Status: Enrolling
Updated: 2/3/2016
Alkermes Investigational Site
mi
from
Bourgas,
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
mi
from
Perry Point, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
mi
from
Perry Point, MD
Click here to add this to my saved trials
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated:  2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
mi
from
New Haven, CT
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated: 2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US009
mi
from
Jacksonville, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US009
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US015
mi
from
Tucson, AZ
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US015
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US019
mi
from
Glendale, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US019
mi
from
Glendale, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US016
mi
from
Oakland, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US016
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US014
mi
from
San Diego, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US014
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US011
mi
from
Denver, CO
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US011
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US018
mi
from
Hallandale Beach, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US018
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US005
mi
from
Orlando, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US005
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US006
mi
from
Gaithersburg, MD
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US006
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US012
mi
from
Weymouth, MA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US012
mi
from
Weymouth, MA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US003
mi
from
Jamaica, NY
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US003
mi
from
Jamaica, NY
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US001
mi
from
Dayton, OH
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US001
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US007
mi
from
Portland, OR
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US007
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US004
mi
from
Memphis, TN
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US004
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US002
mi
from
Seattle, WA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US002
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Kansas
mi
from
Wichita, KA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Marlton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Global Medical Institutes, Llc
mi
from
Princeton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Global Medical Institutes, Llc
mi
from
Princeton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Michael R Liebowitz MD
mi
from
New York, NY
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Michael R Liebowitz MD
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Phildadelphia, PA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Phildadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Salt Lake City, UT
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Alabama Office of Psychiatric Clinical Research
mi
from
Birmingham, AL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Alabama Office of Psychiatric Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
mi
from
Encino, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials